Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications - investor.lilly.com

As reported by Lilly.com

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Lilly.com ↗

Market Samachar is a news aggregator. This article was originally published by Lilly.com. Tap the button above to read the full story on their site.

COMPANIES Two Adani Group stocks in focus as GQG sells stake in Rs 5,750 crore deal; SBI MF lone buyer Stocks-Markets-Economic Times
COMPANIES Adani Green Energy among 5 stocks flashing bullish signals, hinting at a possible uptrend Stocks-Markets-Economic Times
COMPANIES ECB to hike rates as Mideast war pushes up inflation Stocks-Markets-Economic Times
INDIAN Cryptocurrency exchange Bybit to open SpaceX tokenized IPO access Markets-Economic Times
INDIAN CMR Green Technologies IPO allotment today: Check status online as GMP signals 34% listing premium Markets-Economic Times
COMPANIES Merritronix shares to list today. GMP hints at strong SME debut Stocks-Markets-Economic Times
INDIAN Rupee opens 37 paise lower at 95.32 against US dollar mint - markets
INDIAN Hexagon Nutrition IPO Day 2: Issue subscribed 1.65x so far. Check GMP, issue details, key dates. Apply or not? mint - markets

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications - investor.lilly.com

More from Market Samachar